[1] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 中华内科杂志,2016,55（1）:57-72.
[2] 李敏然,徐小元. 肝硬化门静脉高压食管胃静脉曲张出血的防治研究. 中华肝脏病杂志,2015,23（4）:247-249.
[3] 戴光荣,谭玉娥,刘文娜,等. Logistic回归分析食管静脉曲张破裂出血的危险因素. 实用肝脏病杂志. 2015,18（4）:387-390.
[4] Tripathi D,Stanley AJ,Hayes PC,et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut,2015,pii:gutjnl-2015-309262.
[5] Qi XS,Bao YX,Bai M,et al. Nonselective beta-blockers in cirrhotic patients with no or small varices:a meta-analysis. World J gastroenterol,2015,21（10）:3100-3108.
[6] D'Amico G,Pagliaro L,Bosch J. Pharmacological treatment of portal hypertension:an evidence-based approach. Semin Liver Dis,1999,19（4）:475-505.
[7] Sinagra E,Perricone G,D’Amico M,et al. Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther,2014,39（6）:557-568.
[8] Gluud LL,Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrance Database Syst Rev,2012,8:CD004544.
[9] The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Pophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized,single-blind,multicenter clinical trial. N Engl J Med,1991,324（25）:1779-1784.
[10] Lo GH,Chen WC,Wang HM,et al. Randomized,controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol,2012,27（11）:1681-1687.
[11] Stanley AJ,Dickson S,Hayes PC,et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol,2014,61（5）: 1014-1019.
[12] Mustafa MZ,Stanley A. Variceal rebleeding:use of drug therapy and endoscopic band ligation. Expert Rev Gastroenterol Hepatol, 2014,8（2）:179-183.
[13] 中华医学会消化内镜学分会食管胃静脉曲张学组. 消化道静脉曲张及出血的内镜诊断和治疗规范试行方案（2009年）. 中华消化内镜杂志,2010,27（1）:1-4.
[14] Gonzalez R,Zamora J,Gomez-Camarero J,et al. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med,2008,149（2）:109-122.
[15] Funakoshi N,Ségalas-Largey F,Duny Y,et al. Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding:a meta-analysis. World J Gastroenterol,2010,16（47）:5982-5992.
[16] Puente A,Hernández-Gea V,Graupera I,et al. Drugs plus ligation to prevent rebleeding in cirrhosis:an updated systematic review. Liver Int,2014,34（6）:823-833.
[17] Halabi SA,Sawas T,Sadat B,et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients:A Meta-analysis of randomized controlled trials. J Gastroenterol Hepatol,2016,doi:10.1111.
[18] Mishra SR,Sharma BC,Kumar A. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers:a randomized controlled trial. J Hepatol,2011,54（6）:1161-1167.
[19] Gu J,Zhang Q,Xue D,et al. A randomized controlled study of fuzheng huayu capusule for prevention of esophageal variceal bleeding in patients with liver cirrhosis. Evid Based Complement Alternat Med,2013,2013:534960. |
